New drug shields celiac patients from gluten damage in early trial
NCT ID NCT06001177
First seen Jan 05, 2026 · Last updated May 05, 2026 · Updated 18 times
Summary
This study tested an experimental drug called KAN-101 in 55 adults with celiac disease who had been on a gluten-free diet for at least a year. The goal was to see if the drug could reduce damage to the small intestine caused by a two-week gluten challenge. Results suggested KAN-101 helped protect the gut lining compared to a placebo, but more research is needed to confirm long-term safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Albert Schweitzer Ziekenhuis, locatie Dordwijk
Dordrecht, South Holland, 3318AT, Netherlands
-
Alliance for Multispecialty Research, LLC
Wichita, Kansas, 67207, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CRST Helsinki Oy
Helsinki, Uusimaa, 00180, Finland
-
Centre Intégré de Santé et de Services Sociaux-Chaudière Appalaches - Hôtel-Dieu de Lévis
Lévis, Quebec, G6V 3Z1, Canada
-
Centrum Medyczne Med-Gastr Sp. z o.o.
Lodz, Łódź Voivodeship, 91-034, Poland
-
Clinical Research Services Turku
Turku, Southwest Finland, 20520, Finland
-
Connolly Hospital
Dublin, Dublin, D15X40D, Ireland
-
Diex Recherche Quebec Inc.
Québec, Quebec, G1V 4T3, Canada
-
Gastromed Sp. z o. o.
Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
-
Homestead Associates in Research Inc.
Miami, Florida, 33032, United States
-
Hopital Du Sacre-Coeur De Montreal
Montreal, Quebec, H4J 1C5, Canada
-
LHSC
London, Ontario, N6A 5W9, Canada
-
MZ Badania Slowik Zymla Spolka Jawna
Knurów, Silesian Voivodeship, 44-190, Poland
-
McMaster University
Hamilton, Ontario, L8S 4L8, Canada
-
Melita Medical
Wroclaw, Lower Silesian Voivodeship, 50-449, Poland
-
Midland Regional Hospital Mullingar
Mullingar, Westmeath, N91Na43, Ireland
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
Our Lady of Lourdes Hospital
Drogheda, Louth, A92VW28, Ireland
-
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907, United States
-
Rabin Medical Center
Petah Tikva, Central District, 4941492, Israel
-
Shaare Zedek Medical Center
Jerusalem, Jerusalem, 9103102, Israel
-
Sheba Medical Center
Ramat Gan, Central District, 5265601, Israel
-
Soroka Medical Center
Beersheba, Southern District, 8410101, Israel
-
Studiengesellschaft BSF Unternehmergesellschaft
Halle, Saxony-Anhalt, 6108, Germany
-
Tays Research Services
Tampere, Pirkanmaa, 33520, Finland
-
Unlimited Medical Research Group
Hialeah Gardens, Florida, 33018, United States
-
WIP Warsaw IBD Point Profesor Kierkuś
Warsaw, Masovian Voivodeship, 00-728, Poland
Conditions
Explore the condition pages connected to this study.